Vinay Prasad, a senior vaccine official at the U.S. Food and Drug Administration (FDA), is set to leave the agency again at the end of April following renewed controversies surrounding vaccine and drug reviews. The development was announced by FDA Commissioner Marty Makary, who informed staff in an internal email that Prasad would step down from his position and return to academia.

Prasad currently serves as one of the FDA’s top vaccine regulators and has been closely involved in evaluating vaccines and related pharmaceutical products. According to reports cited by the Associated Press, his departure follows disputes linked to regulatory decisions and interactions with pharmaceutical companies, including Moderna. The disagreements reportedly contributed to growing tensions within the agency regarding vaccine review processes.

This marks Prasad’s second exit from the FDA in less than a year, highlighting ongoing debates inside the agency over how vaccines and drugs should be evaluated and approved. Critics and supporters have long debated his regulatory approach, particularly his outspoken views on evidence standards, clinical trial data, and the pace of approvals for new medicines. The controversies surrounding these issues have placed him at the centre of several high-profile policy discussions.

Also Read: US Pressures Sri Lanka To Keep Iranian Sailors After Warship Strike

Before his role at the FDA, Prasad was widely known for his academic work and commentary on medical research, clinical trials, and health policy. He has held a faculty position at the University of California, San Francisco (UCSF), where he focused on oncology, epidemiology, and evidence-based medicine. His research and public commentary have often addressed the need for stricter scientific standards in evaluating drugs and medical treatments.

Prasad’s tenure at the FDA drew attention partly because of his public criticism of aspects of the pharmaceutical industry and regulatory decision-making. He has frequently argued that regulators must maintain rigorous evidence thresholds when approving vaccines and therapies, particularly when public health and patient safety are involved. Such positions sometimes placed him in disagreement with pharmaceutical companies and even colleagues within regulatory institutions.

With Prasad expected to return to his academic role at UCSF, the FDA will likely begin searching for a replacement to oversee vaccine regulation at a time when global attention on drug approval standards and public health oversight remains high. The agency continues to play a critical role in reviewing vaccines, biologics, and medicines that affect millions of people in the United States and worldwide.

Also Read: Brent Oil Crosses $90 A Barrel, Records Biggest Weekly Gain Since Pandemic